Discover key insights from Cytokinetics' Q2 2025 earnings call, including aficamten’s regulatory progress, launch plans, clinical milestones, and ...

Discover Trevi Therapeutics' Q2 2025 progress, featuring groundbreaking CORAL & RIVER trial data, a $204M cash position, and plans for multiple Phase ...

GAAP EPS loss of $1.71 in Q2 2025 slightly missed the consensus estimate by $0.01; revenue remains at zero (GAAP) in Q2 2025, as expected for a clinical-stage biotech. Operating loss (GAAP) widened to ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a ...

Claiming it wants to cut waste, the Trump administration has terminated grants for research testing ways to save the health ...

Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Veracyte ...

Consuming fewer calories is largely accepted as a way to improve health and lose weight, but a recently published study in Nature Metabolism points to ...

Q2 2025 Management View CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel ...